Drug-Related Problems in Neonatal Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

512 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-01

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Drug-related problems in newborn babies have been reported with a rate of 4-30%. It is estimated that the higher rates of these problems in hospitalized children under the age of two are related to the variety of drugs used and the differences in the age, weight and diagnosis of the patients. In this context, with the clinical parameters and demographic data obtained in the first 24 hours of the patients hospitalized in the neonatal intensive care unit, machine learning algorithms are used to predict the risks that may arise from possible drug-related problems (prescribing and administration errors, side effects and drug-drug interactions) that may occur during hospitalization. The algorithm, which will be created by modeling with a high number of big data pool, is planned to be transformed into a clinical decision support system software that can be used easily in clinical practice with online and mobile applications. By processing the data of the patients to be included in the model, it is aimed to prevent and manage drug-related problems before they occur, as well as to provide cost-effective medşcation treatment to patients hospitalized in the neonatal intensive care unit, together with a reduction in the risk of drug-related mortality and morbidity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amikacin Pharmacokinetics to Optimize Dosing Recommendations in Neonates With Perinatal Asphyxia Treated With Hypothermia

NCT04867993

Asphyxia Neonatorum

UNKNOWN NA

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

NCT04104646

Neonatal Opioid Withdrawal Syndrome

TERMINATED PHASE2

Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention

NCT02125201

Pain

COMPLETED PHASE4

How to Treat Opiate Withdrawal in Neonates

NCT02810782

Neonatal Abstinence Syndrome

COMPLETED PHASE3

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260

Neonatal Opiate Withdrawal Syndrome

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal Intensive Care Unit Medication Errors Drug-Related Problems Adverse Drug Event Drug-Drug Interaction Clinical Pharmacy Machine Learning

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational Group

Group Type NO_INTERVENTION

No interventions assigned to this group

Control (Validation) Group

Group Type NO_INTERVENTION

No interventions assigned to this group

İnterventional Group

Group Type EXPERIMENTAL

Clinical Pharmacist Intervention

Intervention Type DRUG

Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical Pharmacist Intervention

Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newborns aged 0-28 days,
* Consent form taken by the parents to participate in the study,
* Patients admitted to neonatal intensive care unit or surgical wards

Exclusion Criteria

* Have a postnatal age greater than 28 days,
* Patients who will not be given any medication,
* Patients who took part in any drug research within the last 28 days

Minimum Eligible Age

1 Hour

Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No